The Parkinson’s Virtual Biotech is pleased to announce the appointment of eminent expert Dr Richard Seabrook PhD MBA as a non-executive Director of NRG Therapeutics.
Richard brings over 25 years of experience in scientific translation working with companies, charities and universities to accelerate drug development.
During his time at The Wellcome Trust Richard established a £200 million Seeding Drug Discovery fund which facilitated small molecule development and early stage clinical studies and saw over 30 of its programmes progress to the clinic or to product approval stage.
His appointment completes the formation of an outstanding Board where he will join Arthur Roach, Parkinson’s UK Director of Research, in supporting the NRG Therapeutics management team in their quest to discover and develop a potential drug that could safeguard dopamine cells damaged by Parkinson’s and slow the progression of the condition.
Richard comments on his new role:
“I’m very excited to be joining the team at NRG Therapeutics, their biological insights into mitochondrial dysfunction and world class drug discovery expertise has the potential to yield novel disease modifying approaches to Parkinson’s and it’s complications.”
Dr Neil Miller, Founder and CEO of NRG Therapeutics, adds:
“I am delighted to welcome Richard onto the NRG Therapeutics Board. His expertise in building early-stage drug-discovery companies and helping them successfully translate their scientific discoveries will be extremely valuable to the company over the next 2-3 years. We look forward to working with him in delivering novel medicines for people affected by devastating neurodegenerative disorders such as Parkinson’s.”